ArticleFrontiers in pharmacology2026
Antithrombotic therapy for hepatic artery thrombosis following liver transplantation: a case report and literature review.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic artery thrombosis (HAT) is one of the most severe complications following liver transplantation (LT). Its prevention requires balancing the risks of bleeding and embolism. Due to the incomplete recovery of the coagulation and fibrinolytic system function in LT patients and considerable individual variability, there is currently no standardized protocol for HAT prevention. Case Presentation: This report presents a case of HAT in a patient with liver failure following LT. Following surgical thrombectomy and hepatic artery resection and anastomosis, the patient received combined antiplatelet and parenteral anticoagulant therapy during hospitalization. At discharge, sequential therapy was transitioned to direct oral anticoagulants (DOACs) for long-term prevention of HAT recurrence, resulting in favorable outcomes. This study also reviews relevant studies on HAT following LT and summarizes the current evidence-based treatment and antithrombotic prophylaxis strategies for HAT. Conclusion: Antithrombotic strategies vary according to the center. Although antiplatelet therapy has the highest level of evidence for HAT prevention, recent clinical experience also suggests a role for anticoagulants in selected patient populations. Regimen selection requires balancing thrombotic and hemorrhagic risks. In this case, we found that novel biomarkers (e.g., thrombin-antithrombin and plasmin-α2-plasmin inhibitor complexes) may guide anticoagulation decisions, and DOACs represent a promising long-term option for HAT prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.